Investigation of Plasminogen Activator Inhibitor-1 4G/5G Gene Polymorphisim in Patients with Pre-Diagnosed Cerebrovascular Disease, Coagulation Disorder and Hypertension

Ahmet Dönder 1 * , Ragıp Balahoroğlu 1, Mehmet Ramazan Şekeroğlu 1, Haluk Dülger 2 3
More Detail
1 Yüzüncü Yıl University, Faculty of Medicine, Department of Biochemistry, Van, Turkey
2 Necmettin Erbakan University, Faculty of Medicine, Department of Biochemistry, Konya, Türkiye
3 Mevlana University, Faculty of Medicine, Department of Biochemistry, Konya, Türkiye
* Corresponding Author
EUR J BASIC MED SCI, Volume 3, Issue 3, pp. 56-60. https://doi.org/10.21601/ejbms/9203
OPEN ACCESS
Download Full Text (PDF)

ABSTRACT

Plasminogen activator inhibitor-1 (PAI-1); gene polymorphism is the main inhibitor of fibrinolysis, and high levels may increase the risk of cardiovascular disease. The polymorphism of the 4G/5G gene is located in the PAI-1 gene promoter region. In this study, our objective is to investigate the genotype and allele distributions of PAI-1 gene polymorphisms in patients with cerebrovascular disease, coagulation disorder and those pre-diagnosed with hypertension. The results of the analysis PAI-1 gene polymorphism in 109 patients were evaluated retrospectively. These patients were divided into three groups as cerebrovascular disease, hypertension and coagulation disorder. In the analysis, CVD T (cardiovascular disease thrombosis) stripassay kit which is based on reverse hybridization technique was used. No statistically significant difference was found between three groups in terms of genotype and allele frequencies. PAI-1 4G/5G genotype in cerebrovascular disease and hypertension groups were found to be statistically significant compared with 4G/4G genotype, in terms of intra group comparison of genotype distrubutions of the group. In the group pre-diagnosed with coagulation disorder PAI-1 4G/5G genotype were found to be statistically significant compared with 4G/4G and 5G/5G. In conclusion; PAI-1 4G/5G genotype may be evaluated a risk factor in patients cerebrovascular disease, coagulation disorder and hypertension.
Keywords: plasminogen activator inhibitor-1, PCR, polymorphism, 4G/5G

CITATION

Dönder A, Balahoroğlu R, Şekeroğlu MR, Dülger H. Investigation of Plasminogen Activator Inhibitor-1 4G/5G Gene Polymorphisim in Patients with Pre-Diagnosed Cerebrovascular Disease, Coagulation Disorder and Hypertension. Eur J Basic Med Sci. 2013;3(3):56-60. https://doi.org/10.21601/ejbms/9203

REFERENCES

  • Hamsten A, Wiman B, de Faire U, Blomback M. Increased plasma levels of a rapid inhibitor of tissue plasminogen activator in young survivors of myocardial infarction. N Engl J Med 1985; 313: 1557-63.
  • Dobrovolsky AB, Titaeva EV. The fibrinolysis system: regulation of activity and phsiologic functions of its main components. Biochem 2002; 67: 99-108.
  • Eriksson P, Kallin B, van’t Hooft FM, Bavenholm P, Hamsten A. Allele specific increase in basal transcription of the plasminogen-activator inhibitor-1 gene is associated with myocardial infarction. Proc Natl Acad Sci USA 1995; 92: 1851-5.
  • Ashavaid TF, Todur SP, Kondkar AA, et al. Platelet polymorphisms: frequency distribution and association with coronary artery disease in an Indian population. Platelets 2011; 22: 85-91.
  • Abboud N, Ghazouani L, Saidi S, et al. Association of PAI-1 4G/5G and -844G/A gene polymorphisms and changes in PAI-1/tissue plasminogen activator levels in myocardial infarction: a case control study. Genet Test Mol Biomarkers 2010; 14: 23-7.
  • Pawse AR, Tarachand U. Clot lysis: role of plasminogen activator inhibitors in haemostasis and therapy. Indian J Exp Biol 1997; 35: 545-52.
  • Martínez-Calatrava MJ, Gonzalez-Sanchez JL, Zabena C, et al. Is the plasminogen activator inhibitor-1 gene a candidate gene predisposing to hypertension? Results from a population-based study in Spain. J Hypertens 2007; 25: 773-7.
  • Jeng JR. Association of PAI-1 gene promoter 4G/5G polymorphism with plasma PAI-1 activity in Chinese patients with and without hypertension. American Journal of Hypertension 2003; 16: 290-6.
  • Song Y, Xu W, Chen Y, et al. The influences of genetic and environmental factors on plasma plasminogen activator inhibitor-1 levels in patients with essential hypertension. Zhonghua Yi Xue Yi Chuan Xue Za Zhi 1999; 16: 374-6.
  • Margaglione M, Cappucci G, Colaizzo D, et al. The PAI-1 gene locus 4G/5G polymorphism is associated with a family history of coronary disease. Arteriosclerosis Thrombosis Vascular Biology 1998; 18: 152-6.
  • Catto AJ, Carter AM, Stickland M, et al. Plasminogen activator inhibitor-1 (PAI-1) 4G/5G promoter polymorphism and levels in subjects with cerebrovascular disease. Thromb Haemost 1997; 77: 730-4.
  • Gardemann A, Lohre J, Katz N, et al. The 4G4G genotype of the plasminogen activator inhibitor 4G/5G gene polymorphism is associated with coronary atherosclerosis in patients at high risk for this disease. Thromb Haemost 1999; 82: 1121-6 (Abstract).
  • Ding J, Nicklas BJ, Fallin MD, et al. Plasminogen activator inhibitor type-1 gene polymorphisms and haplotypes are associated with plasma plasminogen activator inhibitor type 1 levels but nor with myocardial infarction or stroke. American Heart Journals, 2006; 152: 1109-15.
  • Onalan O, Balta G, Oto A, et al. Plasminogen activator inhibitor-1 4G4G genotype is associated with myocardial infarction but not with stable coronary artery disease. J Thromb Thrombolysis 2008; 26: 211-7.
  • Zhan M, Zhou Y, Han Z. Plasminogen activator inhibitor-1 4G/5G gene polymorphism in patients with myocardial or cerebrovascular infarction in Tianjin. China Chin Med J 2003; 116: 1707-10.
  • Wiklund P, Nilsson L, Ardnor SN, et al. Plasminogen activator inhibitor-1 4G/5G polymorphism and risk of stroke: Replicated findings in two nested case-control studies based on independent cohorts. Stroke 2005; 36: 1661-5.
  • Balta G, Altay Ç, Gurgey A. PAI-1 Gene 4G/5G Genotype: A Risk Factor For Thrombosis in Vessels of Internal Organs. Am J Hematol 2002; 71: 89-93.
  • Kim KN, Kim KM, Kim BT, et al. Relationship of plasminogen activator inhibitor 1 gene 4G/5G polymorphisms to hypertension in Korean women. Chin Med J 2012; 125: 1249-53.
  • Akhter MS, Biswas A, Ranjan R, et al. Plasminogen activator inhibitor-1 (PAI-1) gene 4G/5G promoter polymorphism is seen in higher frequency in the Indian patients with deep vein thrombosis. Clin Appl Thromb Hemost 2010; 16: 184-8.